Interview with Andrew Giddy, CEO, Nucleus Network
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Address: 5th Floor, Burnet Tower, AMREP Precinct ,89 Commercial Road,Melbourne, Victoria, Australia, 3004
Tel: + 613 9076 8900
Web: http://www.nucleusnetwork.com.au/page.aspx?54
Nucleus Network is committed to operational and service excellence. All Nucleus Network’s clinical research is conducted in accordance with internationallyrecognised standards of Good Clinical Practice. Data generated is accepted by all major regulatory jurisdictions including FDA, EMEA and TGA.
Whether you work with Nucleus Network clinical research team, education or consulting personnel, Nucleus Network are committed to providing high quality services and adherence to ethical principles. It is Nucleus Network’s aim to deliver services in a timely and cost-effective manner and to give customers peace of mind. To achieve this, Nucleus Network uses the latest technologies within a coordinated and collaborative framework.
Nucleus Network is committed to quality and continuous improvement in order to meet our clients’ needs for timeliness and high quality data.
Research, Clinical trials
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
See our Cookie Privacy Policy Here